Nucleic Acid Sequence Composition of the Oxford – AstraZeneca Vaccine ChAdOx1 nCoV-19 (AZD1222, Vaxzevria)

Radukic, Marco T.; Le, Dang Thi Thanh; Müller, Kristian M.

doi:10.21203/rs.3.rs-799338/v1

Cited by 2 publications

(2 citation statements)

References 13 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2021-2022, an estimated 50% of the UK's adult population received at least one dose of an adenovirus-vectored SARS-CoV-2 vaccine, predominantly ChAdOx1 17 . The ChAdOx1 vector is based on ChAd-Y25, retaining the ChAd-Y25 hexon and penton 18,19 . ChAd-Y25 has homology to HAdV species E 19 , which is associated with outbreaks of respiratory disease in congregate settings 31 .…”

Section: Ifnγ and Il2 Responses To The Hexon Of The Chadox1 Vector Ch...mentioning

confidence: 99%

“…In addition to the cellular immune landscape of natural HAdV infection, approximately 50% of the UK's adult population have received ChAdOx1, the Oxford-Astra Zeneca SARS-CoV-2 vaccine 17 . This is a viral-vectored vaccine which is based on chimpanzee adenovirus Y25 (GenBank accession: JN254802), and contains a deletion of Y25 genes E4, ORFs 4, 6, 7 and the 34K CDS region and insertion of the equivalent portion of the human adenovirus C5 genome 18,19 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood adenovirus infections and boosted by adenovirus-vectored vaccines

Mukhopadhyay,

Lambisia,

Hoang

et al. 2024

Preprint

View full text Add to dashboard Cite

Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens, and are also used as viral vectors for vaccines and gene therapy products. Preexisting adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon gamma (IFNg) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors, and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNg and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021, and found that homotypic and heterotypic IFNg responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNg responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

show abstract

Section: Ifnγ and Il2 Responses To The Hexon Of The Chadox1 Vector Ch...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood adenovirus infections and boosted by adenovirus-vectored vaccines

Mukhopadhyay,

Lambisia,

Hoang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Uptake of COVISHIELD vaccine and post-vaccination symptoms among healthcare workers at an academic primary care facility in Ghana.

AMOH,

NKETIAH,

BAMFO

et al. 2023

HSI Journal

View full text Add to dashboard Cite

Background: The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected health systems globally. Although a safe, effective, and widely accessible vaccine is crucial to ending the pandemic, the results of studies on the acceptability of vaccines among healthcare workers (HCWs) globally have been conflicting. Documented post-vaccination experiences are also limited. This study describes the uptake of the first dose of the COVISHIELD vaccine and analyses the pattern of post-vaccination symptoms among HCWs in Ghana. Objective: This study sought to assess the uptake of the first dose of the COVISHIELD vaccine and analyse the pattern of post-vaccination symptoms among HCWs. Methods: A cross-sectional survey was conducted at the Korle Bu Polyclinic/ Family Medicine Department (KPFMD) of the Korle Bu Teaching Hospital, Accra, in March 2021. Survey participants (n=188) were staff of the department who completed a structured questionnaire within one week of receiving their first dose of the vaccine. The vaccine uptake rate was estimated from those who received the vaccine (n=255) as a percentage of the total staff number at the department (n=314). Results: The uptake rate of the first dose of the COVISHIELD vaccine among HCWs was 81.2% (n=255/314). The most frequently occurring post-vaccination symptoms were general malaise, headache, injection site pain and swelling, tiredness, muscle aches and fever. These symptoms were largely mild to moderate in severity and occurred mostly within 24 hours after vaccination. Of the 84.6% (n=159) respondents who reported at least one post-vaccination symptom, 77.4% (n=123) took analgesics to manage their symptoms. There was no significant association between age, sex, chronic health condition, a previous positive test for COVID-19 and experiencing post-vaccination symptoms. Conclusion: A high proportion of HCWs received the COVISHIELD vaccine in this study. The study's findings are comparable with prior studies that indicated that the vaccine is generally safe and well-tolerated. Various stakeholders in Ghana should continue to educate, reassure and encourage the population to accept the vaccine as a key intervention towards containing the pandemic.

show abstract

Nucleic Acid Sequence Composition of the Oxford – AstraZeneca Vaccine ChAdOx1 nCoV-19 (AZD1222, Vaxzevria)

Cited by 2 publications

References 13 publications

Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood adenovirus infections and boosted by adenovirus-vectored vaccines

Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood adenovirus infections and boosted by adenovirus-vectored vaccines

Uptake of COVISHIELD vaccine and post-vaccination symptoms among healthcare workers at an academic primary care facility in Ghana.

Contact Info

Product

Resources

About